Skip to main content

Table 1 Clinical characteristics of patients with DLBCL

From: B7-H4 is highly expressed in aggressive Epstein-Barr virus positive diffuse large B-cell lymphoma and inhibits apoptosis through upregulating Erk1/2 and Akt signalling pathways

Characteristics Total(n = 260) EBV-positive(n = 16) EBV-negative(n = 244) P value
No. % No. % No. %
Sex(male/female) 260(157/103) 16(11/5) 244(146/98) 0.492
Age(y) median(range) 55(15–85) 58.5(38–84) 55(15–85)  
Subgroup
 GCB 66/176 37.5 5/15 33.3 61/161 37.9 0.727
 non-GCB 110/176 63.5 10/15 66.7 100/161 62.1
Initial Chemotherapy
 R-CHOP 162/260 62.3 8/16 50.0 154/244 63.1 0.294
 CHOP 69/260 26.5 4/16 25.0 65/244 26.6 0.886
 other 18/260 6.9 1/16 6.3 17/244 7.0 0.913
 no treatment 11/260 4.2 3/16 18.8 8/244 3.3 0.003
Therapeutic response
 CR 108/228 47.6 2/12 16.7 106/216 49.1 0.029
 PR 45/228 19.8 4/12 33.3 41/216 19.0 0.224
 SD 4/228 1.8 0/12 0.0 4/216 1.9 0.634
 PD 71/228 31.3 6/12 50.0 65/216 30.1 0.147
Clinical stage
 I 32/251 12.7 1/15 6.7 31/236 13.1 0.466
 II 39/251 15.5 1/15 6.7 38/236 16.1 0.328
 III 58/251 23.1 0/15 0 58/236 24.6 0.029
 IV 122/251 48.6 13/15 86.7 109/236 46.2 0.002
B symptoms present 95/260 36.5 10/16 62.5 85/244 34.8 0.026
  1. CR Complete remission, PR Partial remisssion, SD Stable disease, PD Progression of disease, R Rituximab
  2. P values are for the comparison of EBV+ and EBVDLBCL patients